EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

HER2-Low Gastric and Gastroesophageal Junction Adenocarcinoma: From Assessment to Treatment Strategies

Alexandra Georgiana Scurtu iD, Daniela Tatiana Sala, Ioan Jung, Tivadar Bara, Radu Mircea Neagoe, Zsolt Zoltán Fülöp iD, Simona Gurzu iD

International Journal of Molecular Sciences · 22.05.2026 · 27 (11) · 4673

DOI: 10.3390/ijms27114673 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.05.2026. Verfasst von Alexandra Georgiana Scurtu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, George Emil Palade University of Medicine, Pharmacy, Science and Technology, 540139 Targu Mures, Romania. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Stomach Neoplasms, Adenocarcinoma, Esophagogastric Junction. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FOCUS: Training and Guidance for UMFST Researchers in Health, European Union.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human epidermal growth factor receptor 2 (HER2) dysregulation contributes to tumorigenesis in gastric and gastroesophageal junction adenocarcinomas (GC/GEJ). HER2 overexpression has been associated in multiple cohorts with aggressive behavior and poor outcomes. While HER2 amplification has long guided therapy in HER2-positive disease, antibody–drug conjugates (ADCs) have shifted attention toward the HER2-low category, typically defined as immunohistochemistry (IHC) 1+ or IHC 2+ with negative in situ hybridization (ISH). This narrative review integrates evidence from the peer-reviewed literature, current testing recommendations, and registered clinical trials. It clarifies practical issues in HER2-low assessment and maps the evolving therapeutic landscape of HER2-targeted ADCs including rational combination strategies that may extend benefit beyond conventionally HER2-positive tumors. A cross-tumor perspective contrasts GC/GEJ testing and biology with the breast cancer paradigm and summarizes the importance of HER2-low expression in non-gastric malignancies. Finally, we discuss the therapeutic strategies in HER2-low GC/GEJ and highlight key safety and monitoring considerations for HER2-directed ADCs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesStomach NeoplasmsAdenocarcinomaEsophagogastric JunctionEsophageal NeoplasmsHumansImmunoconjugatesTrastuzumab

Stichwörter der Autor:innen

HER2-lowantibody–drug conjugatedisitamab vedotingastric cancergastroesophageal junction adenocarcinomatrastuzumab deruxtecan

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, humanImmunoconjugatesTrastuzumab

Autor:innen und Institutionen

  • Department of Pathology, George Emil Palade University of Medicine, Pharmacy, Science and Technology, 540139 Targu Mures, Romania.
  • 2nd Clinic of Surgery, Mureș County Emergency Clinical Hospital, 540136 Targu Mures, Romania.
  • Doctoral School of Medicine and Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science and Technology, 540139 Targu Mures, Romania.
  • Department of Surgery, George Emil Palade University of Medicine, Pharmacy, Science and Technology, 540139 Targu Mures, Romania.
  • Romanian Academy of Medical Sciences, 030167 Bucuresti, Romania.
  • Szegedi Tudományegyetem, Szent-Györgyi Albert Klinikai Központ, Sebészeti Klinika, 6725 Szeged, Hungary.

ORCID-Profile: Alexandra Georgiana Scurtu, Zsolt Zoltán Fülöp, Simona Gurzu

Förderung

  • FOCUS: Training and Guidance for UMFST Researchers in Health
  • European Union

Zitieren

APA

Scurtu, A. G., Sala, D. T., Jung, I., Bara, T., Neagoe, R. M., Fülöp, Z. Z., & Gurzu, S. (2026). HER2-Low Gastric and Gastroesophageal Junction Adenocarcinoma: From Assessment to Treatment Strategies. International Journal of Molecular Sciences, 27(11), 4673. https://doi.org/10.3390/ijms27114673

Vancouver

Scurtu AG, Sala DT, Jung I, Bara T, Neagoe RM, Fülöp ZZ, et al. HER2-Low Gastric and Gastroesophageal Junction Adenocarcinoma: From Assessment to Treatment Strategies. International Journal of Molecular Sciences. 2026;27(11):4673. doi:10.3390/ijms27114673

BibTeX
@article{Scurtu2026,
  author = {Scurtu, Alexandra Georgiana and Sala, Daniela Tatiana and Jung, Ioan and Bara, Tivadar and Neagoe, Radu Mircea and Fülöp, Zsolt Zoltán and Gurzu, Simona},
  title = {HER2-Low Gastric and Gastroesophageal Junction Adenocarcinoma: From Assessment to Treatment Strategies},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {11},
  pages = {4673},
  doi = {10.3390/ijms27114673}
}
Kostenlos starten →